ACE applications are now open through October 15. Join a national network committed to providing high-quality, comprehensive Ataxia care. Apply Now!
When faced with a serious illness and no effective treatment, patients may look to experimental therapies as a last resort. Normally, patients can only access experimental drugs or other investigational medical products through clinical trials. Unfortunately, not everyone can access a clinical trial when they need it. Some live too far Read More…
Written by Yujia Li Edited by Celeste Suart, PhD Walking test in a hospital is not the same as walking at home. Wearable sensors show that real-world walking is more variable than in the hospital. We don’t usually think about how we walk until walking starts to feel different. Walking actually takes more effort than we realize. In spinocerebellar ataxia (SCA) patients, changes Read More…
Written by Carrie Sheeler, PhD Edited by Celeste Suart, PhD Advances in wearable technology for tracking ataxia severity combine coordination changes across different types of movement. How do you know a new treatment is working? This is the key question that clinicians have to answer when developing and testing new therapies. One on one, a patient Read More…
Written by Poojashree Chettiar Edited by Pragya Goel, PhD AI and wearable tech may transform how ataxia is monitored Could everyday devices help track ataxia? Finding treatments for neurological disorders like spinocerebellar ataxias (SCAs) and multiple system atrophy (MSA-C) has been challenging. A major reason is the lack of good Read More…
Escrito por Alexandra PutkaEditado por Dr Hannah K ShorrockTraducido por Ismael Araujo-Aliaga Científicos caracterizan la progresión de las enfermedades SCA1, 2, 3 y 6, y descubren que los síntomas cambian más rápido en los primeros 10 años de la enfermedad. El diseño de ensayos clínicos para enfermedades raras como las Read More…
Written by Alexandra Putka Edited by Dr Hannah K Shorrock Scientists characterize SCA1, 2, 3, & 6 disease progression, finding that symptoms change most rapidly in the first 10 years of the disease. Designing clinical trials for rare diseases such as spinocerebellar ataxias (SCAs) requires us to know the timeline Read More…
Escrito por la Dra. Hannah K ShorrockEditado por la Dra. Larissa Nitschke Las diferencias en el riesgo de por vida en desarrollar la SCA8 están asociados con la presencia de interrupciones en la expansión de repeticiones de ATXN8 En la mayoría de ataxias espinocerebelosas causadas por expansiones de repeticiones, todo Read More…
Escrito por Dr. Gülin ÖzEditado por Dr. Celeste SuartTraduzido por Ana Carolina Martins A ressonância magnética (RM) detecta alterações cerebrais antes dos sintomas de ataxia. A lista de empresas farmacêuticas que direcionaram a sua atenção para as ataxias tem aumentado ao longo da última década. Isto se deve ao promissor Read More…
Written by Alexandra Putka Edited by Dr. Hayley S. McLoughlin Walking measurements detect changes in SCA3 severity across a 1-year study and represent an important biomarker of disease progression Medical doctors use a number of tools to assess a patient’s health: a thermometer and blood pressure monitor, for example. These Read More…
Written by Dr. Hannah K Shorrock Edited by Dr. Celeste Suart Three genetic variants in the NPTX1 gene have been linked to cerebellar ataxia, providing a genetic diagnosis for seven families. Receiving a genetic diagnosis can be incredibly valuable: not only for patients who can access support groups and interact Read More…
